These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35749805)

  • 1. Leukemia derived dendritic cell (DC
    Pepeldjiyska E; Li L; Gao J; Seidel CL; Blasi C; Özkaya E; Schmohl J; Kraemer D; Schmid C; Rank A; Schmetzer HM
    Immunobiology; 2022 Jul; 227(4):152237. PubMed ID: 35749805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture.
    Unterfrauner M; Rejeski HA; Hartz A; Bohlscheid S; Baudrexler T; Feng X; Rackl E; Li L; Rank A; Filippini Velázquez G; Schmid C; Schmohl J; Bojko P; Schmetzer H
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays.
    Schutti O; Klauer L; Baudrexler T; Burkert F; Schmohl J; Hentrich M; Bojko P; Kraemer D; Rank A; Schmid C; Schmetzer H
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes.
    Rackl E; Li L; Klauer LK; Ugur S; Pepeldjiyska E; Seidel CL; Gunsilius C; Weinmann M; Doraneh-Gard F; Reiter N; Plett C; Amberger DC; Bojko P; Kraemer D; Schmohl J; Rank A; Schmid C; Schmetzer HM
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases.
    Baudrexler T; Boeselt T; Li L; Bohlscheid S; Boas U; Schmid C; Rank A; Schmohl J; Koczulla R; Schmetzer HM
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.
    Klauer LK; Schutti O; Ugur S; Doraneh-Gard F; Amberger DC; Rogers N; Krämer D; Rank A; Schmid C; Eiz-Vesper B; Schmetzer HM
    Transfus Med Hemother; 2022 Feb; 49(1):44-61. PubMed ID: 35221867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of Leukaemia-Derived Dendritic Cells (DC
    Schwepcke C; Klauer LK; Deen D; Amberger DC; Fischer Z; Doraneh-Gard F; Gunsilius C; Hirn-Lopez A; Kroell T; Tischer J; Weinmann M; Werner JO; Rank A; Schmid C; Schmetzer HM
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic/antigen presenting cell mediated provision of T-cell receptor gamma delta (TCRγδ) expressing cells contributes to improving antileukemic reactions ex vivo.
    Rackl E; Hartz A; Aslan Rejeski H; Li L; Klauer LK; Ugur S; Pepeldjiyska E; Amend C; Weinmann M; Doraneh-Gard F; Stein J; Reiter N; Seidel CL; Plett C; Amberger DC; Bojko P; Kraemer D; Schmohl J; Rank A; Schmid C; Schmetzer HM
    Mol Immunol; 2024 Nov; 175():40-54. PubMed ID: 39305847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.
    Schick J; Vogt V; Zerwes M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
    J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) - With a focus on Dendritic cells of leukemic origin (DC
    Ansprenger C; Amberger DC; Schmetzer HM
    Clin Immunol; 2020 Aug; 217():108467. PubMed ID: 32464186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PGE
    Amberger DC; Doraneh-Gard F; Gunsilius C; Weinmann M; Möbius S; Kugler C; Rogers N; Böck C; Ködel U; Werner JO; Krämer D; Eiz-Vesper B; Rank A; Schmid C; Schmetzer HM
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31533251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions.
    Merle M; Fischbacher D; Liepert A; Grabrucker C; Kroell T; Kremser A; Dreyssig J; Freudenreich M; Schuster F; Borkhardt A; Kraemer D; Koehne CH; Kolb HJ; Schmid C; Schmetzer HM
    Immunobiology; 2021 May; 226(3):152088. PubMed ID: 33838552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paramunity-inducing Factors (PINDs) in dendritic cell (DC) cultures lead to impaired antileukemic functionality of DC-stimulated T-cells.
    Ansprenger C; Vogt V; Schick J; Hirn-Lopez A; Vokac Y; Harabacz I; Braeu M; Kroell T; Karenberg A; Kolb HJ; Schmetzer H
    Cell Immunol; 2018 Jun; 328():33-48. PubMed ID: 29580554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Leukemic Effects Induced by Dendritic Cells of Leukemic Origin from Leukemic Blood Samples Are Comparable under Hypoxic vs. Normoxic Conditions.
    Doraneh-Gard F; Amberger DC; Amend C; Weinmann M; Schwepcke C; Klauer L; Schutti O; Hosseini H; Krämer D; Rank A; Schmid C; Schmetzer HM
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.
    Schuster FR; Buhmann R; Reuther S; Hubner B; Grabrucker C; Liepert A; Reibke R; Lichtner P; Yang T; Kroell T; Kolb HJ; Borkhardt A; Schmetzer H
    Cancer Genomics Proteomics; 2008; 5(5):275-86. PubMed ID: 19129558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia.
    Plett C; Klauer LK; Amberger DC; Ugur S; Rabe A; Fischer Z; Deen D; Hirn-Lopez A; Gunsilius C; Werner JO; Schmohl J; Krämer D; Rank A; Schmid C; Schmetzer HM
    Clin Immunol; 2022 Sep; 242():109083. PubMed ID: 35908638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of activation, differentiation-markers, or β-integrins on T cells contribute to predict T cells' antileukemic responses after stimulation with leukemia-derived dendritic cells.
    Vogt V; Schick J; Ansprenger C; Braeu M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H
    J Immunother; 2014; 37(6):331-47. PubMed ID: 24911794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
    Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
    J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.